Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct) a randomised, double-blind, placebo-controlled phase 3 trial /
Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants.Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling partici...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | CRITICAL CARE
27 No. 1 |
| Tárgyszavak: | |
| doi: | 10.1186/s13054-022-04205-8 |
| mtmt: | 33560025 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/29641 |
